ImmuCell preliminary Q3 2026 sales $8.0M, up 46% YoY; nine-month sales $25.6M, up 27.8%

IMMUCELL CORP /DE/

Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase over Q3 2025; domestic sales were $6.9 million, up 29.2%.
Nine-month 2026 sales were $25.6 million, a 27.8% increase compared to the nine months ended September 30, 2025.
Growth was broad-based: Tri-Shield rose 51% over Q3 2025, Dual-Force 36%, and the recently launched functional feed line 37%.
CFO Timothy Fiori said the comparison was aided by depressed Q3 2025 sales caused by high distributor purchases in Q2 2025.
ImmuCell will discontinue early sales reporting; CEO Olivier te Boekhorst will discuss full Q3 results on a call November 13, 2026 at 9:00 AM ET.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.